JYPC(SZ:002198) Zheng Quan Zhi Xing·2025-05-23 09:16Agreement Overview - Guangdong Jiaying Pharmaceutical Co., Ltd. signed a technology development contract with Hunan University of Chinese Medicine, establishing a cooperative relationship for the development of a traditional Chinese medicine innovation drug, "Juanbi Lijieqing Granules" [1][2] - The contract does not constitute a related party transaction or a major asset restructuring, thus does not require approval from the shareholders or board of directors [1][2] Contract Details - The contract aims to develop "Juanbi Lijieqing Granules," which is based on a clinically effective formula used for many years [2] - Hunan University of Chinese Medicine will provide the traditional Chinese medicine formula and technical support, while Jiaying Pharmaceutical will conduct all necessary research for new drug registration [2][3] - The project includes pharmacological and toxicological studies, clinical research, and the preparation of registration documents [3][4] Project Responsibilities - Hunan University of Chinese Medicine is responsible for providing the formula and clinical technical support, including clinical positioning and trial design [4] - Jiaying Pharmaceutical will handle the pharmaceutical research, pharmacology, toxicology, and clinical studies necessary for the drug registration [4] Intellectual Property and Profit Sharing - Both parties will jointly apply for patents for any technical achievements resulting from the contract [4] - If the technology is successfully commercialized, profits will be shared based on market valuation or through preferential purchasing by Jiaying Pharmaceutical [4] Impact on the Company - The collaboration is expected to enrich the existing research pipeline and enhance research efficiency, aligning with the company's long-term development strategy and benefiting shareholders [5]